Compare YSS & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YSS | CPRX |
|---|---|---|
| Founded | 2012 | 2002 |
| Country | United States | United States |
| Employees | 710 | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.9B |
| IPO Year | N/A | 2006 |
| Metric | YSS | CPRX |
|---|---|---|
| Price | $20.16 | $31.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 1 |
| Target Price | ★ $36.56 | $35.00 |
| AVG Volume (30 Days) | 1.6M | ★ 1.8M |
| Earning Date | 03-19-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.24 |
| EPS | N/A | ★ 0.50 |
| Revenue | N/A | ★ $119,072,803.00 |
| Revenue This Year | $48.43 | $9.20 |
| Revenue Next Year | $52.83 | $10.51 |
| P/E Ratio | ★ N/A | $62.97 |
| Revenue Growth | N/A | ★ 16.39 |
| 52 Week Low | $16.93 | $19.05 |
| 52 Week High | $44.54 | $32.56 |
| Indicator | YSS | CPRX |
|---|---|---|
| Relative Strength Index (RSI) | 34.02 | 69.77 |
| Support Level | $16.93 | $31.25 |
| Resistance Level | $36.36 | $32.56 |
| Average True Range (ATR) | 2.43 | 0.04 |
| MACD | -0.59 | -0.06 |
| Stochastic Oscillator | 5.56 | 85.71 |
York Space Systems Inc is a U.S.-based space and defense company that provides mission-related solutions for national security, government, and commercial customers. The company develops its own hardware and software, offering capabilities intended to support customer requirements across various elements of the space mission lifecycle. It offers mission solutions across several complementary product categories: Components, Subsystems, Spacecraft Platforms, Ground Operation, Global Downlink, and Software-Enabled Services. The company derives the majority of revenue from long-term firm-fixed-price (FFP) production contracts for the design of small satellites, launch services, and ground services with both U.S. federal government-controlled agencies and domestic commercial customers.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.